Back to top

Image: Bigstock

Avantor (AVTR) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Read MoreHide Full Article

For the quarter ended December 2025, Avantor, Inc. (AVTR - Free Report) reported revenue of $1.66 billion, down 1.4% over the same period last year. EPS came in at $0.22, compared to $0.27 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $1.62 billion, representing a surprise of +3%. The company delivered an EPS surprise of +2.85%, with the consensus EPS estimate being $0.21.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Avantor performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
  • Revenue- Bioscience Production: $547.5 million compared to the $545.34 million average estimate based on five analysts. The reported number represents a change of -2.4% year over year.
  • Revenue- Laboratory Solutions: $1.12 billion compared to the $1.06 billion average estimate based on five analysts. The reported number represents a change of -0.9% year over year.
  • Adjusted Operating Income- Laboratory Solutions: $114.4 million versus $118.63 million estimated by three analysts on average.
  • Adjusted Operating Income- Corporate: $-16 million compared to the $-18.11 million average estimate based on three analysts.
  • Adjusted Operating Income- Bioscience Production: $127 million compared to the $122.96 million average estimate based on three analysts.

View all Key Company Metrics for Avantor here>>>

Shares of Avantor have returned -11.4% over the past month versus the Zacks S&P 500 composite's -0.3% change. The stock currently has a Zacks Rank #2 (Buy), indicating that it could outperform the broader market in the near term.

Zacks' 7 Best Strong Buy Stocks (New Research Report)

Valued at $99, click below to receive our just-released report predicting the 7 stocks that will soar highest in the coming month.

Click Here, It's Really Free

Published in